CU23549A1 - Composiciones farmacéuticas que contienen la proteína nma0939 - Google Patents

Composiciones farmacéuticas que contienen la proteína nma0939

Info

Publication number
CU23549A1
CU23549A1 CU20050279A CU20050279A CU23549A1 CU 23549 A1 CU23549 A1 CU 23549A1 CU 20050279 A CU20050279 A CU 20050279A CU 20050279 A CU20050279 A CU 20050279A CU 23549 A1 CU23549 A1 CU 23549A1
Authority
CU
Cuba
Prior art keywords
nma0939
protein
compositions
pharmaceutical compositions
compositions containing
Prior art date
Application number
CU20050279A
Other languages
English (en)
Other versions
CU23549B7 (es
Inventor
Corona Daniel Yero
Castellanos Agustin Lage
Diaz Darien Garcia
Garcia Gretel Sardinas
Blanco Sonia Gonzalez
Feyt Rolando Pajon
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20050279A priority Critical patent/CU23549A1/es
Priority to ARP060105777A priority patent/AR058735A1/es
Priority to AU2006331224A priority patent/AU2006331224A1/en
Priority to PCT/CU2006/000019 priority patent/WO2007073705A2/es
Priority to BRPI0620867-3A priority patent/BRPI0620867A2/pt
Priority to RU2008131066/13A priority patent/RU2008131066A/ru
Priority to EP06846929A priority patent/EP1977761A2/en
Priority to CA002633424A priority patent/CA2633424A1/en
Priority to CNA200680049521XA priority patent/CN101443037A/zh
Priority to KR1020087018520A priority patent/KR20080081198A/ko
Priority to US12/097,895 priority patent/US20090208521A1/en
Priority to ZA200805355A priority patent/ZA200805355B/xx
Priority to NO20083318A priority patent/NO20083318L/no
Publication of CU23549A1 publication Critical patent/CU23549A1/es
Publication of CU23549B7 publication Critical patent/CU23549B7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con el campo de la medicina, particularmente con el desarrollo de composiciones farmacéuticas que contienen la proteína NMA0939. Las composiciones de la presente invención confieren protección contra diferentes enfermedades, causadas o no por patógenos. La proteína NMA0939 se identificó como componente de las preparaciones de vesículas de membrana externa de Neisseria meningitidis, se obtuvo mediante la tecnología del ADN recombinante y se evaluó su inmunogenicidad y actividad protectora en modelos animales. Por el elevado grado de conservación del gen que codifica para la proteína NMA0939, las composiciones que la contienen poseen alto valor como antígeno inductor de una respuesta inmune de amplia reactividad. Las composiciones de esta invención son aplicables en la medicina humana.
CU20050279A 2005-12-29 2005-12-29 Composiciones farmacéuticas que contienen la proteína nma0939 CU23549A1 (es)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CU20050279A CU23549A1 (es) 2005-12-29 2005-12-29 Composiciones farmacéuticas que contienen la proteína nma0939
ARP060105777A AR058735A1 (es) 2005-12-29 2006-12-26 Composiciones farmaceuticas que contienen la proteina nma 0939
AU2006331224A AU2006331224A1 (en) 2005-12-29 2006-12-28 Pharmaceutical compositions containing protein NMA0939
PCT/CU2006/000019 WO2007073705A2 (es) 2005-12-29 2006-12-28 Composiciones farmacéuticas que contienen la proteína nma0939
BRPI0620867-3A BRPI0620867A2 (pt) 2005-12-29 2006-12-28 formulações farmacêuticas que contêm a proteìna nma0939
RU2008131066/13A RU2008131066A (ru) 2005-12-29 2006-12-28 Фармацевтическая композиция, содержащая белок nma0939
EP06846929A EP1977761A2 (en) 2005-12-29 2006-12-28 Pharmaceutical compositions containing protein nma0939
CA002633424A CA2633424A1 (en) 2005-12-29 2006-12-28 Pharmaceutical compositions containing protein nma0939
CNA200680049521XA CN101443037A (zh) 2005-12-29 2006-12-28 包含蛋白质nma0939的药物组合物
KR1020087018520A KR20080081198A (ko) 2005-12-29 2006-12-28 단백질 ｎｍａ0939를 포함하는 약학적 조성물
US12/097,895 US20090208521A1 (en) 2005-12-29 2006-12-28 Pharmaceutical compositions containing protein nma0939
ZA200805355A ZA200805355B (en) 2005-12-29 2008-06-19 Pharmaceutical compositions containing protein NMA0939
NO20083318A NO20083318L (no) 2005-12-29 2008-07-28 Farmasoytiske sammensetninger inneholdende protein NMA0939

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20050279A CU23549A1 (es) 2005-12-29 2005-12-29 Composiciones farmacéuticas que contienen la proteína nma0939

Publications (2)

Publication Number Publication Date
CU23549A1 true CU23549A1 (es) 2010-07-20
CU23549B7 CU23549B7 (es) 2010-07-20

Family

ID=38218331

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20050279A CU23549A1 (es) 2005-12-29 2005-12-29 Composiciones farmacéuticas que contienen la proteína nma0939

Country Status (13)

Country Link
US (1) US20090208521A1 (es)
EP (1) EP1977761A2 (es)
KR (1) KR20080081198A (es)
CN (1) CN101443037A (es)
AR (1) AR058735A1 (es)
AU (1) AU2006331224A1 (es)
BR (1) BRPI0620867A2 (es)
CA (1) CA2633424A1 (es)
CU (1) CU23549A1 (es)
NO (1) NO20083318L (es)
RU (1) RU2008131066A (es)
WO (1) WO2007073705A2 (es)
ZA (1) ZA200805355B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3035320A1 (en) * 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1185691T3 (da) * 1999-04-30 2009-06-22 Novartis Vaccines & Diagnostic Genomiske neisseriasekvenser og fremgangmåder til anvendelse deraf
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
DE20321889U1 (de) * 2002-08-02 2012-03-12 Glaxosmithkline Biologicals S.A. Impfstoffzusammensetzung
CU23236A1 (es) * 2003-12-03 2007-09-26 Ct Ingenieria Genetica Biotech PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P

Also Published As

Publication number Publication date
NO20083318L (no) 2008-09-26
US20090208521A1 (en) 2009-08-20
AR058735A1 (es) 2008-02-20
ZA200805355B (en) 2009-04-29
WO2007073705A2 (es) 2007-07-05
AU2006331224A1 (en) 2007-07-05
WO2007073705A3 (es) 2007-09-13
RU2008131066A (ru) 2010-02-10
KR20080081198A (ko) 2008-09-08
BRPI0620867A2 (pt) 2011-11-29
EP1977761A2 (en) 2008-10-08
CU23549B7 (es) 2010-07-20
CA2633424A1 (en) 2007-07-05
CN101443037A (zh) 2009-05-27

Similar Documents

Publication Publication Date Title
CY1123152T1 (el) Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους
MX2011000047A (es) Uso de factores de crecimiento recombinantes derivados de plantas en el cuidado de la piel.
BR112012022800A2 (pt) composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
MX2019005268A (es) Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.
CY1119854T1 (el) Ανθρωπινο μονοκλωνικο αντισωμα με ειδικοτητα για ε πρωτεϊνη ιου δαγκειου πυρετου οροτυπου 1 και χρησεις αυτου
AR079197A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
CY1115082T1 (el) Υποκατεστημενα παραγωγα 1,3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων
BR112019002586A2 (pt) proteínas inseticidas
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
CO6400150A2 (es) Proteína de enlace de il-13
MX2021002586A (es) Dosis unitaria de vacuna contra el dengue y administracion de esta.
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
CY1113693T1 (el) Φαρμακευτικες συνθεσεις και μεθοδοι για τον εμβολιασμο κατα της διαχυτης καντιντιασης και αλλων μολυσματικων παραγοντων
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
CY1119073T1 (el) Ισομορφες γλυκοζυλιωσης ανθρωπινης ιστικης καλλικρεινης 1
AR060796A1 (es) Composicion farmaceutica que comprende la proteina nmb0938
AR060797A1 (es) Composicion farmaceutica que comprende la proteina nmb0606
BR112015013625A2 (pt) adjuvante de vacinação, preparação e vacinas contendo o mesmo
CU23549A1 (es) Composiciones farmacéuticas que contienen la proteína nma0939
CU23584A1 (es) Composición farmacéutica que comprende la proteína nmb1796
CU23528A1 (es) Composición farmacéutica que comprende la proteína nmb0848
BRPI0606614A2 (pt) peptìdeos para distribuição de vacinas na mucosa
WO2010080188A3 (en) Epitope targeted anthrax vaccine

Legal Events

Date Code Title Description
FG Grant of patent